Anson Funds Management’s Ensysce Biosciences ENSC Stock Holding History

Anson Funds Management’s Portfolio ENSC Stock Details ENSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-65,568	Closed	-$236K	–	168
2024 Q3	$236K	Buy	+65,568	New	+$398K	0.02%	137
2023 Q3	–	Sell	-2,417	Closed	-$65.3K	–	148
2023 Q2	$65.3K	Buy	+2,417	New	+$109K	0.01%	140
2022 Q3	–	Sell	-42	Closed	-$131K	–	291
2022 Q2	$131K	Sell	42 -479	-92%	-$1.34M	0.01%	293
2022 Q1	$2.14M	Buy	+521	New	+$3.44M	0.17%	108

Other funds holding ENSC

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Anson Funds Management's ENSC Position: Q4 2024 in Review

Anson Funds Management sold out of Ensysce Biosciences (ENSC) in Q4 2024, closing a stake of 65,568 shares — an estimated $236K sold.

Anson Funds Management first reported a position in ENSC in Q1 2022 and held it in 4 quarters. The position peaked at $2.14M in Q1 2022. 8 funds tracked by Wall St. Rank hold ENSC as of Q4 2024.

Anson Funds Management reported no remaining Ensysce Biosciences position as of Q4 2024 after selling out during the quarter.
Anson Funds Management sold 65,568 Ensysce Biosciences shares in Q4 2024, an estimated $236K.
Anson Funds Management first reported a position in Ensysce Biosciences in Q1 2022 and held it in 4 quarters.
Anson Funds Management's Ensysce Biosciences position peaked at $2.14M in Q1 2022.
8 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q4 2024.

Based on Anson Funds Management's 13F filing for Q4 2024, filed 14 Feb 2025.